Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

Income Statement 
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Medtronic PLC, consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Oct 24, 2025 Jul 25, 2025 Apr 25, 2025 Jan 24, 2025 Oct 25, 2024 Jul 26, 2024 Apr 26, 2024 Jan 26, 2024 Oct 27, 2023 Jul 28, 2023 Apr 28, 2023 Jan 27, 2023 Oct 28, 2022 Jul 29, 2022 Apr 29, 2022 Jan 28, 2022 Oct 29, 2021 Jul 30, 2021 Apr 30, 2021 Jan 29, 2021 Oct 30, 2020 Jul 31, 2020 Apr 24, 2020 Jan 24, 2020 Oct 25, 2019 Jul 26, 2019
Net sales 8,961 8,578 8,927 8,292 8,403 7,915 8,589 8,089 7,984 7,702 8,544 7,727 7,585 7,371 8,089 7,763 7,847 7,987 8,188 7,775 7,647 6,507 5,997 7,717 7,706 7,493
Cost of products sold, excluding amortization of intangible assets (3,061) (3,001) (3,146) (2,779) (2,946) (2,761) (3,045) (2,782) (2,761) (2,628) (2,979) (2,689) (2,535) (2,516) (2,591) (2,459) (2,497) (2,598) (2,652) (2,621) (2,705) (2,505) (2,264) (2,400) (2,394) (2,366)
Gross profit 5,900 5,577 5,781 5,513 5,457 5,154 5,544 5,307 5,223 5,074 5,565 5,038 5,050 4,855 5,498 5,304 5,350 5,389 5,536 5,154 4,942 4,002 3,733 5,317 5,312 5,127
Research and development expense (754) (726) (684) (675) (697) (676) (674) (695) (698) (668) (640) (688) (676) (692) (652) (668) (676) (750) (632) (601) (639) (621) (568) (573) (603) (587)
Selling, general, and administrative expense (2,965) (2,806) (2,720) (2,717) (2,757) (2,655) (2,764) (2,673) (2,686) (2,613) (2,616) (2,615) (2,617) (2,567) (2,569) (2,561) (2,615) (2,547) (2,594) (2,537) (2,600) (2,417) (2,359) (2,587) (2,620) (2,543)
Amortization of intangible assets (463) (459) (564) (416) (413) (414) (420) (419) (425) (429) (423) (431) (421) (423) (434) (432) (431) (436) (447) (453) (443) (440) (439) (436) (441) (440)
Restructuring charges, net (10) (45) (147) (43) (30) (47) (112) (20) (40) (54) (293) (38) (30) (14) (27) (12) (10) (11) (60) (83) (97) (53) (31) (13) (27) (47)
Certain litigation charges, net (27) (214) (22) (81) (44) (65) (40) 30 (35) (34) (26) (122) (84) 88 (37) (108) (121) (47)
Other operating income (expense), net (22) (69) (16) 6 35 (3) (477) (17) 31 (2) (59) 126 98 (34) (145) 63 (21) (760) (199) (81) (149) 114 17 39 (149) 22
Operating profit 1,686 1,445 1,436 1,646 1,595 1,278 1,053 1,483 1,340 1,268 1,564 1,392 1,404 1,125 1,671 1,659 1,563 859 1,604 1,277 930 673 316 1,639 1,351 1,485
Other non-operating income, net 92 33 (1) 73 173 157 6 177 153 76 173 150 109 83 74 67 66 111 103 86 65 82 51 96 108 101
Interest expense, net (181) (176) (174) (179) (209) (167) (203) (188) (180) (148) (187) (167) (118) (164) (143) (137) (136) (137) (141) (143) (470) (171) (162) (156) (165) (609)
Income before income taxes 1,597 1,302 1,261 1,540 1,559 1,268 856 1,472 1,313 1,196 1,550 1,375 1,395 1,044 1,602 1,589 1,493 833 1,566 1,220 525 584 205 1,579 1,294 977
Income tax (provision) benefit (216) (255) (200) (237) (281) (219) (196) (135) (402) (399) (361) (146) (960) (113) (109) (106) (176) (64) (200) 59 (31) (93) 434 340 77 (100)
Net income 1,381 1,047 1,061 1,303 1,278 1,049 660 1,337 911 797 1,189 1,229 435 931 1,493 1,483 1,317 769 1,366 1,279 494 491 639 1,919 1,371 877
Net income attributable to noncontrolling interests (7) (7) (5) (9) (8) (7) (6) (15) (2) (6) (9) (7) (8) (2) (8) (3) (6) (6) (6) (9) (5) (4) 7 (4) (7) (13)
Net income attributable to Medtronic 1,374 1,040 1,056 1,294 1,270 1,042 654 1,322 909 791 1,180 1,222 427 929 1,485 1,480 1,311 763 1,360 1,270 489 487 646 1,915 1,364 864

Based on: 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).


The financial performance over the reported quarters exhibits distinct patterns and fluctuations across key metrics.

Net Sales
Net sales generally increased over the periods, with occasional declines. The trend reveals a recovery and growth phase following a dip around early 2020, likely impacted by external factors. From mid-2020 onwards, sales showed progressive growth, culminating in higher sales figures toward the end of the timeline.
Cost of Products Sold
The cost of products sold remained somewhat stable with moderate fluctuations. There is a noticeable increase in costs in certain periods, particularly around early 2021 and mid-2023, paralleling the rise in net sales but with less volatility.
Gross Profit
Gross profit trends mirror those of net sales, with an initial decline in early 2020 followed by steady improvement. The gross profit margin appears to be maintained effectively, as profit values increase in line with net sales growth, indicating sustained operational efficiency.
Research and Development Expense
Research and development expenses showed slight variability, generally maintaining a consistent level throughout the periods. Some increases, notably in later quarters, suggest ongoing investment in innovation despite fluctuations in revenue.
Selling, General, and Administrative Expense (SG&A)
SG&A expenses remained relatively stable with minor ups and downs. The values indicate controlled administrative and sales expenses, even as net sales and gross profit figures evolved, reflecting disciplined cost management.
Amortization of Intangible Assets
Amortization charges were generally consistent, with a mild downward trend in certain periods followed by irregular spikes, which may relate to asset acquisitions or amortization policy changes.
Restructuring Charges, Net
Restructuring charges varied considerably, with some significant spikes, particularly one notable peak in early 2023. Such charges suggest periods of organizational realignment or cost restructuring to optimize operations.
Certain Litigation Charges, Net
Litigation charges were irregular and sporadic, with alternating positive and negative values. This reflects cyclical or one-off legal matters impacting the financials unpredictably.
Other Operating Income (Expense), Net
Other operating income and expenses presented volatile amounts, including some substantial negative values, indicating occasional operational gains or losses outside core activities affecting profitability in certain quarters.
Operating Profit
Operating profit showed substantial recovery after a pronounced dip in early 2020, tracking upward with growing net sales and controlling costs. Some quarters experienced reduced operating profit due to increased restructuring or unusual operating expenses.
Other Non-operating Income, Net
This income component generally contributed positively with minor fluctuations, supporting overall profitability.
Interest Expense, Net
Interest expense declined significantly in early periods, stabilizing afterward with moderate fluctuations, indicating effective debt management and reduced financing costs over time.
Income Before Income Taxes
Income before income taxes reflected the operating profit and non-operating income trends, with a strong recovery post-2020-related downturn and peaks aligning with high operating profits and controlled expenses.
Income Tax (Provision) Benefit
Income tax provisions exhibited volatility, including some quarters of significant tax expense spikes, which impacted net income disproportionately in selected periods.
Net Income
Net income followed the general recovery pattern seen in operating profit, with strong increases after early 2020 lows. Despite some pressure from income tax provisions and restructuring, net income attained notable highs in recent quarters.
Net Income Attributable to Noncontrolling Interests
Values were minor in magnitude and fluctuated between small positive and negative amounts, indicating limited but variable impact on consolidated net income from noncontrolling interests.
Net Income Attributable to the Company
Net income attributable to the company represented the majority of consolidated net income, demonstrating a recovery trend consistent with overall profitability improvements in the reported quarters.